Research programme: PSMA ATAC therapeutics - Heidelberg Pharma

Drug Profile

Research programme: PSMA ATAC therapeutics - Heidelberg Pharma

Alternative Names: PSMA antibody drug conjugates - Heidelberg Pharma

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Heidelberg Pharma
  • Class Drug conjugates; Immunotoxins
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 18 Oct 2016 Research programme: PSMA ATAC therapeutics - Heidelberg Pharma is available for licensing as of 13 Oct 2016. http://www.heidelberg-pharma.com/
  • 28 Jun 2016 Heidelberg Pharma has patent protection for chemical synthesis of dihydroxyisoleucine in European Union
  • 30 Jun 2015 Preclinical trials in Prostate cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top